US Patent Issued to Beijing Giluntide Pharmaceutical on March 17 for "Rk polypeptide radiopharmaceutical targeting HER2 and preparation method thereof" (Chinese Inventors)

ALEXANDRIA, Va., March 17 -- United States Patent no. 12,576,170, issued on March 17, was assigned to Beijing Giluntide Pharmaceutical Co. Ltd. (Beijing).

"Rk polypeptide radiopharmaceutical targeting HER2 and preparation method thereof" was invented by Fan Wang (Beijing), Jiyun Shi (Beijing), Shuaifan Du (Beijing) and Bing Jia (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed are an rk polypeptide radiopharmaceutical targeting HER2, and a preparation method therefor. The rk polypeptide radiopharmaceutical comprises an rk polypeptide dimer and a radionuclide, wherein the radionuclide marks the rk polypeptide dimer by means of a chelating agent, the rk polypeptide dimer is a polypeptide dimer ...